Table 2.
Summary of progression-free survival, overall survival and objective response results
| RAS wild-type | RAS wild-type/BRAF wild-type | |||
|---|---|---|---|---|
| Panitumumab + mFOLFOX6 (n = 88) | Bevacizumab + mFOLFOX6 (n = 82) | Panitumumab + mFOLFOX6 (n = 77) | Bevacizumab + mFOLFOX6 (n = 79) | |
| Progression-free survival | ||||
| Patients with event, n (%) | 64 (73) | 70 (85) | 55 (71) | 67 (85) |
| Median, months (95% CI) | 12.8 (10.7, 15.1) | 10.1 (9.0, 12.7) | 13.1 (11.6, 16.2) | 10.1 (9.0, 12.7) |
| HR (95% CI) | 0.68 (0.48, 0.96) | 0.61 (0.42, 0.88) | ||
| p value* | 0.029 | 0.0075 | ||
| Overall survival | ||||
| Patients with event, n (%) | 57 (65) | 58 (71) | 48 (62) | 55 (70) |
| Median, months (95% CI) | 36.9 (27.9, 46.1) | 28.9 (23.3, 32.0) | 41.3 (31.6, 46.7) | 28.9 (23.9, 33.1) |
| HR (95% CI) | 0.76 (0.53, 1.11) | 0.70 (0.48, 1.04) | ||
| p value* | 0.15 | 0.08 | ||
| Subsequent therapy | ||||
| Anti-EGFR mAb, n (%) | 28 (32) | 41 (50) | 27 (35) | 40 (51) |
| Anti-VEGF mAb, n (%) | 44 (50) | 31 (38) | 39 (51) | 30 (38) |
| Objective response† | ||||
| Responders,‡ n | 57 | 49 | 50 | 48 |
| ORR,‡ % (95% CI) | 65 (54, 75) | 60 (49, 71) | 65 (53, 75) | 62 (50, 72) |
| Difference in rates, % (95% CI) | 4.3 (−10.9, 19.3) | 3.4 (−12.5, 19.0) | ||
| Odds ratio¶ (95% CI) | 1.12 (0.56, 2.22) | 1.11 (0.54, 2.27) | ||
| p value§ | 0.86 | 0.90 | ||
CI confidence interval, EGFR epidermal growth factor receptor, HR hazard ratio, mAb monoclonal antibody, ORR objective response rate, RECIST Response Evaluation Criteria In Solid Tumours, VEGF vascular endothelial growth factor, WT wild type
*From stratified Cox model
†For the objective response analysis, n = 81 for the RAS WT bevacizumab group and n = 78 for the RAS WT/BRAF WT bevacizumab group
‡As assessed by RECIST
¶Defined as the odds of having an objective response in the panitumumab + mFOLFOX6 arm relative to the odds in the bevacizumab + mFOLFOX6 arm
§From stratified exact test